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Abstract: 
 
The discovery that PARP inhibitors block an essential pathway of DNA repair 
in cells harbouring a BRCA mutation has opened up a new therapeutic 
avenue for high-grade ovarian cancers. BRCA1 and BRCA2 proteins are 
essential for high-fidelity repair of double-strand breaks of DNA through the 
homologous recombination repair (HRR) pathway. Deficiency in HRR (HRD) 
is a target for PARP inhibitors. The first PARP inhibitor, olaparib, has now 
been licensed for BRCA–mutated ovarian cancers. Whilst mutated BRCA 
genes are individually most commonly associated with HRD other essential 
HRR proteins may be mutated or functionally deficient potentially widening the 
therapeutic opportunities for PARP inhibitors. HRD is the first phenotypically 
defined predictive marker for therapy with PARP inhibitors in ovarian cancer. 
Several different PARP inhibitors are being trialled in ovarian cancer and this 
class of drugs has been shown to be a new selective therapy for high-grade 
ovarian cancer. Around 20% of high-grade serous ovarian cancers harbour 
germline or somatic BRCA mutations and testing for BRCA mutations should 
be incorporated into routine clinical practice. The expanded use of PARP 
inhibitors in HRD deficient (non-BRCA mutant) tumours using a signature of 
HRD in clinical practice requires validation. 
 
Introduction: 
 
Until recently, the treatment of ovarian cancer has not been adapted to 
histological or biological variability in the tumour. Surgery and platinum-taxane 
chemotherapy remain the cornerstone of primary treatment followed at 
recurrence by further platinum-based chemotherapy until the tumour becomes 
‘platinum-resistant’. It is now clear that epithelial ovarian cancer (EOC) 
comprises several different diseases [1, 2]. The collective term represents a 
distinct and diverse group of molecularly and aetiologically distinct pathologies 
with differing clinical behaviour (Figure 1). If the outcome of advanced ovarian 
cancer is to improve then our approach to treatment and the development of 
novel agents must target and exploit distinct subgroups within this 
heterogeneity.  
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Around 70% of EOC are high-grade serous adenocarcinomas. A defining 
feature of this subtype is the presence of mutations within the tumour 
suppressor gene p53 [3, 4]. In addition, molecular analysis of high-grade 
serous ovarian cancer (HGSOC) by The Cancer Genome Atlas (TCGA) has 
shown that around half have aberrations in homologous recombination repair 
(HRR), a critical DNA damage response pathway [5]. Repair of DNA damage 
following platinum-based therapy has long been considered an important 
determinant of tumour chemosensitivity. Several genetic lesions causing 
homologous recombination deficiency (HRD) include germline and somatic 
BRCA mutations as well as mutations of genes such as ATM, CHEK2, RAD51 
and MRE11A (Table 1), and epigenetic silencing have been described in 
HGSOC. Exploitation of HRD by inhibitors of PARP (poly ADP ribose 
polymerase) a DNA repair enzyme involved in base-excision repair producing 
further disruption of DNA damage repair has formed the basis of a new 
molecularly targeted therapeutic strategy to treat ovarian cancer [6]. Over the 
last decade, studies with inhibitors of DNA repair, specifically PARP inhibitors 
in BRCA-mutated ovarian cancers have resulted in truly personalized 
medicine in ovarian cancer.  
 
Here we review the central role of homologous recombination deficiency 
(HRD) in broadening the application of PARP inhibitors as monotherapy or in 
combination with other agents in ovarian cancer, and discuss how testing for 
HRD will become a key requirement for future trials and treatment decisions.  
 
 
Biology: 
 
DNA damage response and repair pathways:  
 
The recognition and subsequent repair of DNA damage is essential for normal 
cellular function and maintenance of genomic stability. In humans acquired or 
inherited defects in DNA repair pathways result in an increased lifetime risk of 
cancer [7]. To date 450 genes are implicated in the DNA damage response 
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and repair [8] and these genes can be sub-grouped, by function, into five 
distinct pathways [9]. Each pathway, shown in figure 2a, has evolved to deal 
with a specific type of DNA damage, although there is some overlap in their 
functions. DNA double-strand breaks (DSB), the most lethal insult to the 
genome, left un-repaired result in genomic instability and cell death [10] . DSB 
can arise as a result of direct damage to both strands of DNA from exogenous 
anti-cancer treatments such as ionising radiation or the topoisomerase 
inhibitors [5] or as part of normal physiology e.g. to permit genetic 
recombination during meiosis [11]. DNA double-strand breaks can be repaired 
by multiple pathways. The classical non-homologous end-joining (C-NHEJ) 
pathway relies on the hetero-dimer Ku 70/Ku80, and ligates DSB ends without 
a template, it is active throughout the cell cycle. Homologous recombination 
repair (HRR), shown in figure 2 is an error-free pathway that uses a 
homologous DNA template to repair DSB and is initiated by end resection 
from the DNA break ends to generate a long stretch of single-strand DNA for 
strand invasion. HRR is used when cells enter S and G2 because cyclin-
dependent kinases are needed for promoting end resection and to activate 
HRR. Microhomology-mediated end joining (MMEJ) is a back-up pathway and 
enables Ku independent alternative NHEJ [12]. It like HRR requires cyclin-
dependent kinase activities and increases when cells enter S phase. MMEJ 
shares the initial end resection step with HRR but does not require S139-
phosphorylated histone H2AX (γ-H2AX), suggesting that initial end resection 
likely occurs at DSB ends.  
A significant number of DSB  arise during DNA replication when a replication 
fork encounters an unrepaired SSB; the HRR pathway together with the 
nuclear enzyme, PARP-1, are particularly important to repairing these 
collapsed replication forks [13, 14]. The HRR pathway involves the function of 
both the BRCA1 and BRCA2 proteins. BRCA1 becomes part of a large 
complex associated genome surveillance complex (BASC). BASC is thought 
to act as a sensor for the DSB DNA damage and includes: the MRN complex, 
mismatch repair proteins (MSH2, MSH6 and MLH1), BLM syndrome helicase 
and ATM [15]. BRCA2 has a more direct role in repair through its regulation of 
the Rad51 recombinase. It has been suggested that the BRCA2-Rad51 
complex binds to the exposed DNA, and this enables the loading of Rad51 on 
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to the break and the formation of the presynaptic filament [16]. Deficiency in 
BRCA1 or BRCA2 results in HRR deficiency (HRD), and this can 
therapeutically exploited by PARP inhibitors. 
 
 
Development of PARP inhibitors and Synthetic lethality: 
 
The first PARP enzyme of the 17 member nuclear super-family was 
discovered over 50 years ago [17] and the first PARP inhibitor (3-
aminobenzamide) 20 years later [18]. Today’s small molecule PARP inhibitors 
mediate their anti-cancer effects as catalytic inhibitors blocking repair of DNA 
single strand breaks by the BER/SSBR pathway. The initial clinical 
development of PARP inhibitors as cancer treatments focused on their role as 
chemo-sensitisers, and there was no scientific rationale that they would have 
single-agent activity. However in 2005, two articles published in Nature 
reported that cells deficient in BRCA1 and 2 were 100- to 1000-fold more 
sensitive to PARP inhibitors than BRCA1/2 heterozygote or wild-type cell lines 
[19, 20]. Bryant et al [19] used the PARP inhibitors NU1025 and AG14361, a 
forerunner to rucaparib (Clovis Oncology). Farmer et al [20] demonstrated the 
sensitivity of two small molecule inhibitors KU0058684 and KU0058948, 
forerunners to olaparib. Both research groups independently concluded that 
the BRCA-deficient cells were selectively sensitive to PARP inhibition by a 
mechanism of ‘synthetic lethality’. 
This is a process by which cancer cells are selectively targeted by the 
inactivation of two genes or pathways when inactivation of either gene or 
pathway alone is non-lethal.  The term, originally used by geneticists in the 
1940s  was proposed as a possible anti-cancer strategy in the late 1990s [21]. 
In this case PARP inhibitors inhibit the repair of single strand DNA breaks by 
the BER/SSBR pathway and these accumulate and left unrepaired result in 
DNA DSB which must be repaired for cell survival. In the setting of HRD e.g. 
due to a BRCA mutation then these DNA DSB cannot be accurately and 
efficiently repaired and the PARP inhibition ultimately results in cell death. 
Recent reports have challenged this hypothesis and proposed alternative 
models of synthetic lethality [22]. For example, it is now known that PARP 
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inhibitors themselves can be directly toxic to cells by trapping PARP-1 and 2 
at the site of the damaged DNA [23]. These trapped PARP-DNA complexes 
may in turn obstruct replication forks, which require BRCA-dependent HRR to 
be resolved. Interestingly, depleting PARP with PARP inhibitors has been 
shown to be more cytotoxic than depleting PARP through siRNA [24]. It is 
also known that PARP itself is critical to mediate Mre11-dependent replication 
restart at stalled replication forks and this is also relevant to the mechanism of 
synthetic lethality [14]. 
Clinical trials were initiated a decade ago to explore whether PARP inhibitors 
could through a model of synthetic lethality be therapeutically active in 
tumours defective in HRR. 
 
Clinical experience of PARP inhibitors in ovarian cancer: 
 
The first phase I trial was performed in a group of patients enriched for a 
BRCA mutation using AZD2281, an oral PARP inhibitor acquired from Kudos 
by AstraZeneca and later called olaparib. The activity of olaparib soon 
became clear as almost half the heavily pre-treated ovarian cancer patients 
responded, and the drug was associated with only minor side effects [25] . An 
expanded phase I trial was then performed in 48 patients with BRCA-mutated 
ovarian cancer, one patient with a variant BRCA mutation of unknown 
significance and another with a strong family history of breast/ovarian cancer. 
A tumour response, measured by RECIST or CA125 fall, was seen in 20 
(40%) patients and the median duration of response was 28 weeks. The study 
included 24 patients with ‘platinum-resistant’ and 13 with ‘platinum-refractory’ 
disease [26]. The clinical benefit rate (response and disease stabilization) was 
greatest among patients with ‘platinum-sensitive’ disease. The activity of 
olaparib in BRCA-related ovarian cancer was confirmed in a sequential two-
dose cohort study of 400mg and 100 mg bd. An overall response rate of 33% 
was seen in patients receiving the higher dose, and 13% with 100mg bd [27]. 
 
The initial development strategy of olaparib compared the activity of olaparib 
with pegylated liposomal doxorubicin (PLD) in a group of women with BRCA-
mutated recurrent ovarian cancer (Study 12). In this small three-arm 
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randomized trial (with 200 and 400 mg dose-levels of olaparib) the 
progression-free survival (PFS) with olaparib and PLD were similar. The 
expected response rate to olaparib was confirmed, but the progression-free 
survival to PLD in women with BRCA-mutated ovarian cancer was higher than 
expected [28].  
 
The integrity of BRCA proteins is key to effective HRR, although other 
proteins are also important for this process [29]. Data began to emerge 
demonstrating that somatic mutations or methylation of BRCA as well as 
dysfunction of other HR-related proteins could be associated with a ‘platinum-
sensitive’ phenotype in high grade ovarian cancer potentially selecting for 
sensitivity to PARP inhibitors [3, 30].  These data suggested HRD could result 
from genetic lesions other than germ line BRCA mutations. This observation 
also strongly implied that PARP inhibitors might have clinical utility in a larger 
group of women with ovarian cancer. To explore this hypothesis further, a 
large randomized placebo-controlled trial was designed to include patients 
who were likely to have an ‘HRD phenotype’, by selecting a population of 
women with high-grade serous cancer and ‘platinum-sensitivity’ following 
repeated platinum therapies (study 19). This was a maintenance study in 
which olaparib was given following a response to platinum-based therapy [31]. 
The presence of a BRCA mutation was not required but it was anticipated that 
the population would be enriched for a BRCA mutation because of the above 
entry criteria. During the trial, data emerged that olaparib was active in 24% of 
46 patients with high grade serous ovarian cancer without a germ line BRCA 
mutation[32]. Study 19 demonstrated a clear benefit of maintenance olaparib, 
with an extension in the progression-free survival from the start of 
maintenance treatment from 4.8 to 8.4 months (hazard ratio: 0.35; 95% CI, 
0.25 to 0.49; P<0.001). About 22% of the patients had a BRCA mutation and 
14 % were known to be BRCA negative. An early  analysis of overall survival 
showed no benefit, which led to a more detailed study of BRCA status of the 
entire population. Information on BRCA status in both germ line and tumour 
became available in 96% of patients. Overall, 51 % had either a germ line or 
somatic mutation of BRCA. In the BRCA-mutated group the PFS was 11.2 
months compared to 4.3 months in patients on placebo (hazard ratio: HR 
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0·18; 95% CI, 0·10–0·31; p<0·0001). In the 118 patients in the BRCA-wild 
type group there was still a significant benefit in favour of olaparib, although 
less marked (hazard ratio: 0·54; 95% CI 0·34–0·85; p=0·0075) [33]. Survival 
data are still immature for both the BRCA-mutated and overall population. 
There is a non-significant OS trend in favour of olaparib, but the results are 
confounded by cross-over to a PARP inhibitor in subsequent studies in 23% 
of the population. Nevertheless, the beneficial value of olaparib was further 
supported by secondary endpoint analyses, such as time to first subsequent 
therapy after progression and time to second subsequent therapy and led in 
December 2014 to approval of the drug by the European Medicines Agency 
for maintenance therapy in relapsed HGSOC following a response to 
platinum-based therapy. Additional supportive data has also come from a 
study in ‘platinum-sensitive’ ovarian cancer in which olaparib was given with 
carboplatin and paclitaxel and then as maintenance. In study 41 no additive 
benefit was seen with chemotherapy, but the PFS of the group receiving 
olaparib was significantly longer than in those receiving chemotherapy alone 
(HR 0·51 [95% CI 0·34–0·77]; p=0·0012) and the effect was even greater in 
the small number of patients with a known BRCA mutation[34]. In the USA the 
FDA licensed olaparib as monotherapy therapy in patients with BRCA-
mutated ovarian cancer who have received three or more lines of treatment. 
The evidence for this was derived mainly from ‘study 42’ [35], a trial of 
monotherapy with additional data from earlier trials. The licence was based on 
the data of 137 patients and the response rate was 34% with an average 
response duration of 7.9 months [36]. 
 
Olaparib, ten years after entering clinical trials is now established as a 
treatment for BRCA-mutated ovarian cancer. Side effects from treatment are 
generally mild, with fatigue, nausea and anaemia being the most commonly 
reported adverse events. Diarrhoea, altered taste, headache and ‘cold-like’ 
symptoms have also been reported. Two rare but serious side effects are 
pneumonitis and myelodysplastic syndrome/ AML. The latter has been 
reported in patients with a BRCA mutation and it is not clear by how much the 
risk is increased with olaparib. No significant detrimental effects have been 
seen in Quality of Life measurements [37] and only 7 (5%) patients on study 
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19 discontinued olaparib due to adverse events. Some patients have 
remained on treatment for several years. Careful monitoring for long-term 
toxicities continues but the number of cases of myelodysplasia or acute 
leukaemia remains very low, less than 1% of more than 22,000 patients. 
Olaparib is currently formulated as a capsule and the recommended dose of 
400 mg twice daily requires that women take 16 capsules per day. A new 
tablet formulation, 300mg twice daily is being evaluated in new, ongoing 
studies including SOLO-2, a randomized maintenance trial in high-grade 
carcinomas with a BRCA mutation (NCT01874353).  
 
Overcoming resistance to PARP inhibitors 
Despite reports of prolonged clinical responses to the PARP inhibitor olaparib 
[38] the majority of ovarian cancers become resistant to treatment.  There are 
several mechanisms by which resistance to PARP inhibitors can occur. 
Primary resistance often occurs in tumours that do not have HRD, which is 
likely to be in around 50% of high-grade serous ovarian cancer cases. 
Induction of HRD in ovarian cancer to overcome resistance by altering the 
tumour microenvironment through hypoxia [39] or by combining PARP 
inhibitors with agents that might down-regulate HRR, such as PI3Kinase 
inhibitors [40] might render HRR competent cells sensitive to PARP inhibition. 
This concept, known as ‘contextual’ synthetic lethality, could have some effect 
on primary resistance and possibly broaden the application of this class of 
drugs in the treatment of cancer, and is the rationale behind other ongoing 
combination studies. Acquired resistance to PARP inhibitors in BRCA-
mutated tumours may be more difficult to overcome; mechanisms have been 
demonstrated in preclinical models and patients, which include secondary 
molecular defects that partly restore BRCA function, increasing drug efflux 
mediated by overexpression of P-glycoprotein and most recently reduced or 
absent 53BP1 [41-43] (figure 3). 
 
The majority of PARP inhibitor studies have excluded patients with prior 
PARP inhibitor exposure and so there are as yet no clinical reports of 
repeated therapy, or using a different PARP inhibitor in previously treated 
tumours. It is also unknown whether re-treatment with other PARP inhibitors 
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that are either more potent (in vitro), such as BMN673 (talazoparib) [44] or 
have distinct inhibitory profiles such as rucaparib (inhibits tankyrases) will 
overcome resistance seen with another PARP inhibitor. What is clear is that 
patients who develop resistance do respond to subsequent therapies [45] 
allaying some of the concern that prolonged therapy with a PARP inhibitor 
may induce platinum and other drug resistance.  
 
Defining the HRD population: 
 
Maintenance trials with other PARP inhibitors, such as niraparib and 
rucaparib, two PARP inhibitors that are active as monotherapy in BRCA-
mutated ovarian cancer [46, 47] are in progress (NOVA; NCT01847274 and 
ARIEL3; NCT01968213). Importantly these trials include patients without a 
BRCA-mutation, testing the hypothesis that PARP inhibitor therapy could be 
useful in a wider group of patients. Defining HRD is not straightforward as it 
represents a phenotypic behaviour of tumour cells resulting from one or more 
abnormalities in the many proteins responsible for HRR. In addition to germ 
line BRCA mutations, other less common germ line and/or somatic mutations 
involved in HRD and predictive of a response to platinum may be present in 
almost one third of ovarian tumours [48]. Gene expression analysis has been 
explored to identify ‘BRCAness’, a phenotype that correlates with ‘platinum-
sensitivity’ [49] but a clinically useful prospective test for HRD is needed for 
decision-making. Simple tests, such as immunochemistry to identify Rad51 
foci, involved in the HRR process have been difficult to set up, and it is 
unlikely that these will be easily applicable to clinical practice [50]. The Clovis 
Oncology Group in combination with Foundation Medicine are exploring 
genomic scarring as a marker for a ‘BRCA-like’ state. The first results of 
ARIEL2, a trial of rucaparib in predominantly BRCA-wild type ‘platinum 
sensitive’ tumours was able to dichotomise patients into ‘BRCA-like’ and 
biomarker negative tumours with response rates (RECIST/CA125) to 
rucaparib in 45% and 21 % respectively [51]. It is clear that if the indication for 
PARP inhibitors is to expand into a BRCA-wild type population robust tests 
with a high probability of determining HRD status are needed. 
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PARP inhibitors in a wider population of ovarian cancer: 
 
Data are emerging to show that tumour activity may be increased by 
combining olaparib with cediranib, an anti-VEGFR tyrosine kinase inhibitor 
[52]. A randomized trial of ‘platinum-sensitive’ ovarian cancer, demonstrated 
an additive effect of the combination resulting in a median progression free 
survival of 17.7 months compared to 9 months for olaparib alone. A subset 
analysis of outcome by BRCA status suggested that the greater benefit of the 
combination was seen in patients without a BRCA mutation. A hypothesis to 
consider is that the enhancing effect was due to an increase in HRD with 
cediranib due to tumour hypoxia [53, 54]. Two other studies with cediranib 
and olaparib are being planned, one comparing the combination with 
chemotherapy being conducted by the NCI-CTEP, and the other, the UK-led 
ICON9 trial adding olaparib to cediranib as maintenance treatment after 
chemotherapy with cediranib. A randomised first-line trial adding olaparib 
maintenance to chemotherapy and bevacizumab is has just opened 
(PAOLA1). Variation in the amount of HRD present in the tumours of these 
patients is likely to be an important factor that affects outcome, but until 
validated prospective tests are available, stratification on the basis of a BRCA 
mutation is all that can be reliably achieved. 
 
Selecting OC Patients for PARP Inhibitor Therapy  
The significant positive impact of PARP inhibition in the management of 
ovarian cancer will require a change in practice. A single approach to therapy 
for ovarian cancer is no longer valid. Identification of patients with a BRCA 
mutation is already an important consideration in routine clinical practice. 
Hitherto, testing of patients with a BRCA mutation has been focussed on risk-
identification and risk-reduction in unaffected family members of women [55].  
However, selecting patients for testing on the basis of family history alone is 
insufficient; studies testing cohorts of women with ovarian cancer have 
consistently shown that around 30% of women with a germ line BRCA 
mutation do not have a known family history of breast or ovarian cancer [56, 
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57]. The estimated frequency of a germ line BRCA mutation in high-grade 
ovarian cancer is around 15%[58], although probably higher when restricted 
to high-grade serous cancers, and about 10 fold higher among the Israeli 
Ashkenazi Jewish population where it accounts for 40% of ovarian cancer  
[59]. The activity of PARP inhibitors in patients with somatic BRCA mutations 
appears to be similar to those with germ line mutations [33], and somatic 
mutations are present in around 6-8% of cases [60]. Updated results from the 
ARIEL2 trial of   rucaparib in 152 patients with ‘platinum-sensitive’ ovarian 
cancer and wild-type BRCA reported a response rate of 36% in patients with a 
‘BRCA-like’ signature, in contrast to 16% in patients that were biomarker 
negative [61]. It is likely on the basis of these results that a strategy will need 
to be developed to routinely test tumours for the presence of HRD.  
Identification of patients who harbour a BRCA mutation has therapeutic 
implications for the individual and possible consequences for non-affected 
mutation carriers. As many ovarian cancer patients with a BRCA mutation do 
not have a family history, all patients with high-grade cancers should be 
counselled for a germ line mutation testing. The presence of a BRCA mutation 
has wider implications for women with ovarian cancer that has led some to 
recommend that all patients should be referred to genetics departments for 
counselling and testing. However, for many departments, the number of 
referrals would be overwhelming. This has led to the concept of genetic 
mainstreaming, an approach where counselling and testing take place within 
the Gynaecological Oncology environment with referral of positive cases to 
genetic clinics for family counselling and testing. Pilot studies have shown this 
to be feasible [62] and as the cost of testing falls, the prospect of routine 
testing of patients for germ line mutations is less daunting for funders. 
Nevertheless, the diagnosis of a germ line mutation in patients with ovarian 
cancer carries with it an extra burden; what to do about breast cancer 
prevention and how to deal with the often complex family dynamics 
surrounding the diagnosis in one family member. Guidelines for testing will 
need to be adapted but even with the current approach genetic counselling 
and testing remains under-utilised[63]. The introduction of olaparib into clinical 
practice has increased the number of centres and regions now establishing 
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routine testing for most women with high-grade serous ovarian cancer. 
However, the funding for olaparib is not uniform throughout Europe and this 
may affect the speed with which routine testing is implemented. In reality, not 
all ovarian cancer patients with a BRCA mutation will respond to a PARP 
inhibitor, and for some the duration of response is short. Little is known about 
the underlying factors affecting the duration of response. Also, some of the 
mutations detected may not be known to be pathogenic, and are called 
‘variants of unknown significance’ (VUS). Sharing of data amongst geneticists 
and genetics laboratories is needed to improve the interpretation of these 
VUS [64]. 
However, restricting tests to measurement of germ line BRCA mutations will 
miss somatic mutations and other causes of HRD. There are at least 12 
inherited genes associated with the HRD phenotype [65] (Table 1) in addition 
to somatic BRCA mutations. Mutations in these non-BRCA HRD genes are 
uncommon. It has been suggested that all patients should have tumour 
testing for at least a somatic BRCA mutation. However, interpretation of 
results may not always be straightforward, and there is uncertainty about how 
many of the HRD-related genes should be tested. Other measurements of 
genomic instability, such as the degree of genomic scarring (loss of 
heterozygosity (LOH)) may provide valuable supplementary information to 
mutational analysis [66]. This will become more important if current trials with 
niraparib or rucaparib maintenance therapy lead to licensing of the drugs in 
the non-BRCA group. There are arguments for testing tumour first and only 
referring patients with a BRCA mutation to geneticists for counselling and 
germ line testing. 
Companion diagnostic HRD tests are being developed alongside the 
maintenance trials of PARP inhibitors in NOVA (niraparib) and ARIEL3 
(rucaparib). One is in collaboration with Myriad Genetics [67] which uses three 
combined measures to provide an HRD score - loss of heterozygosity, 
telomeric allelic imbalance and large-scale state transitions in cancer cells 
[68]. A novel genetic biomarker test developed in collaboration with 
Foundation Medicine, based on the assessment of genomic instability by 
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measuring loss of heterozygosity (LOH) across the whole genome, expressed 
as a measure of ‘genomic scarring’ [69], reported  with the updated results of 
ARIEL2 [61] will be used in ARIEL3. 
Research that started by exploring that activity of PARP inhibitors in tumours 
harbouring a germ line BRCA mutation has identified a new molecularly 
defined genetic predictive marker for response. In parallel, work on DNA 
damage response repair and more complex genomic analysis of tumours has 
demonstrated the complexity of the HRD phenotype. At the same time these 
simultaneous advances have provided an opportunity to expand therapeutic 
research with PARP inhibitors. The interaction of PARP inhibitors with other 
molecularly targeted therapies such as inhibitors of angiogenesis further 
widens the potential clinical benefit of these drugs. A new paradigm for 
treatment is rapidly emerging, underpinned by a better understanding of the 
molecular processes that are defective in ovarian cancer. This is allowing 
clinicians to offer a molecularly selected patient population an effective 
treatment with low toxicity and durable benefit.  
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Table 
 
 
HR-pathway 
gene 
Observed 
Frequency 
All Epithelial 
Ovarian Cancer (%) 
Observed 
frequency High 
Grade Ovarian 
Cancer (%) 
 
Reference 
RAD51C 0.41 – 2.9 1.9 [48, 70-72] 
RAD51D 0.35 – 1.1 0.95 [3, 48, 72] 
RAD51B 0.06 0.95 [3, 72] 
RAD50 0.2 - [70] 
RAD54L - 0.5 [61] 
ATM 0.8 - 0.86 0.32 - 1.0 [3, 48, 70] 
BRIP1 0.9 – 1.72 0.32 - 1.0 [3, 48, 73] 
CHEK2 0.4 – 1.6 0.32 - 1.0 [3, 48, 70] 
FANCA - 0.5 [61] 
FANCI - 0.5 [61] 
NBN 0.2 – 0.25 0.63 - 1.0 
[3, 48, 70, 
73] 
PALB2 0.2 – 0.5 0.63 [3, 48, 73] 
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Figure 1: Histological and molecular sub-types of EOC. g=germline, t= tumour 
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Figure 2 
 
 
 
 
 
 
 
 
 
 
  
Figure 2a: The five DNA repair pathways in man 
Figure 2b: DNA double strand break repair by 
Homologous recombination repair (HRR) 
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Figure 3: The three known mechanisms of acquired resistance to PARP 
inhibitors. 53BP1 (p53 binding protein, also called TP53BP1) is a chromatin-
associated factor that promotes immunoglobulin class switching and DNA 
double-strand-break (DSB) repair by non-homologous end joining.  
PGp = P-glycoprotein 
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